Get the Stockscreener App
3.06
0.65%
-0.02
Pre-market:
3.11
0.05
+1.63%
Prokidney Corp stock is traded at $3.06, with a volume of 987.81K.
It is down -0.65% in the last 24 hours and up +26.45% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$3.08
Open:
$3.08
24h Volume:
987.81K
Relative Volume:
0.45
Market Cap:
$413.08M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-5.3684
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
-4.38%
1M Performance:
+26.45%
6M Performance:
+245.53%
1Y Performance:
+91.25%
1-Day Range:
$3.035
$3.13
1-Week Range:
$2.90
$3.4799
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
3.06 | 418.81M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
Automated trading signals detected on ProKidney Corp.Weekly Trend Recap & AI Driven Stock Movement Reports - newser.com
Is now a turning point for ProKidney Corp.Weekly Investment Summary & Consistent Income Trade Ideas - newser.com
Heatmap analysis for ProKidney Corp. and competitorsJuly 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
What valuation multiples suggest for ProKidney Corp. stockJuly 2025 Catalysts & Weekly Momentum Picks - newser.com
What to expect from ProKidney Corp. in the next 30 daysPortfolio Profit Report & Trade Opportunity Analysis - newser.com
Visual analytics tools that track ProKidney Corp. performancePortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Will ProKidney Corp. stock recover faster than peersShare Buyback & Verified Momentum Stock Watchlist - newser.com
Will ProKidney Corp. stock go up soonRisk Management & Long-Term Safe Investment Ideas - newser.com
Will ProKidney Corp. stock beat EPS estimatesWeekly Risk Summary & Precise Trade Entry Recommendations - newser.com
How ProKidney Corp. stock performs in stagflationSwing Trade & Community Trade Idea Sharing - newser.com
Is ProKidney Corp. stock poised for growthQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
What technical charts say about ProKidney Corp. stockJuly 2025 EndofMonth & Growth Oriented Trading Recommendations - newser.com
ProKidney (NASDAQ:PROK) Shares Down 8.2%Should You Sell? - MarketBeat
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference - The Manila Times
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - Investing News Network
Guidance Update: Can ProKidney Corp. stock weather global recessionJuly 2025 Institutional & Daily Risk Controlled Trade Plans - fcp.pa.gov.br
Prokidney’s Long-Term Study on Renal Therapy: A Potential Game Changer for CKD - TipRanks
Prokidney’s REACT Study: A Potential Game Changer for Kidney Disease Treatment - TipRanks
Prokidney’s Long-Term Study on REACT Therapy: A Potential Game-Changer for CKD - TipRanks
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):